AngioDynamics, Inc. Earnings Recaps
Q3 2026
Apr 2, 2026
AngioDynamics delivered another strong quarter, demonstrating sustained top-line growth and expanding profitability driven by robust performance in Med Tech and thrombectomy portfolios. The company continues to execute on strategic priorities, raising full-year guidance for the third consecutive quarter.
Key takeaways
- Med Tech segment, led by Auryon, achieved 19th consecutive quarter of double-digit YoY growth, supported by international expansion post-CE Mark.
- Thrombectomy portfolio (AlphaVac and AngioVac) grew approximately 18% YoY, with AlphaVac showing record sequential revenue increase and positive clinical adoption.
- NanoKnife saw notable growth in disposables and capital, with expanded European indications and a favorable CMS CPT 1 code rollout bolstering market access.
- The company reaffirmed its strategic focus on large, high-margin markets amid macro uncertainties, leveraging innovation and clinical milestones.
- Full-year revenue and EBITDA guidance were raised for the third straight quarter, reflecting confidence in continued profitable growth.
Q2 2026
Jan 6, 2026
AngioDynamics reported strong overall performance in Q2 FY2026, with revenue growth of 8.8% and nearly doubled adjusted EBITDA year-over-year, prompting an increase in full-year guidance.
Key takeaways
- MedTech revenue surged by 13%, driven primarily by continued strong performance from the Auryon platform, marking its 18th consecutive quarter of double-digit growth.
- Significant regulatory advancements were achieved in the mechanical thrombectomy portfolio, including IDE approvals for key studies that enhance competitive positioning and clinical applications.
- The NanoKnife system benefitted from increased procedure volumes following the recent CPT code activation, positioning the company well for future market growth.